ArticleAMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science2023
Unsupervised Anomaly Detection to Characterize Heterogeneity in Type 2 Diabetes.
Article in AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is associated with heterogeneous behaviors affecting patients' clinical characteristics and trajectories. This study includes 21,288 patients with type 2 diabetes (women, ages 30 to 65). The cohort was filtered through a set of preprocessing heuristics in order to assure the cohort exhibited a similar clinical trajectory. Anomalous characteristics were then identified using dimensionality reduction and anomaly detection methods. Compared to the majority of the cohort, patients classified as anomalous were twice as likely to be admitted into the hospital (7.94[7.59 8.28] versus 3.12[3.06 3.17] times), have a higher incidence of comorbidities (2[1.64 2.36] times more), and be prescribed more insulin and less new and more expensive diabetes medications (such as Sodium glucose co-transporter 2 inhibitors). Patients with these anomalous characteristics may benefit from additional or specialized interventions to avert their risk for adverse outcomes.
Identifiers
37350904PMC10283093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.